Ista Anticipates Bepotastine NDA Filing In 2007 For Allergic Conjunctivitis
This article was originally published in The Pink Sheet Daily
Executive Summary
The ophthalmic company licensed the investigational eye drop formulation from Senju for $6 mil. in up-front and potential milestone payments.
You may also be interested in...
Ista Gains North American Rights To Bepotastine For Nasal Allergies From Tanabe Seiyaku
H1 receptor antagonist will enter clinic for nasal indication in late 2008/early 2009, firm tells “The Pink Sheet” DAILY.
Ista Gains North American Rights To Bepotastine For Nasal Allergies From Tanabe Seiyaku
H1 receptor antagonist will enter clinic for nasal indication in late 2008/early 2009, firm tells “The Pink Sheet” DAILY.
Ista Files Fixed-Dose Combination Ophthalmic T-Pred With FDA
T-Pred combines prednisolone acetate and tobramycin for treatment of inflammatory ocular conditions.